I D
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILEEQUIPMENT & SERVICESFOCUSNEW PRODUCTS + Show More SHOW PREVIEWS

Comment uncategorized

Lonza to build new small-molecule manufacturing plant in Switzerland

By Mary Page Bailey |

Lonza AG (Basel, Switzerland) announced the construction of a new small molecule manufacturing complex at its Visp, Switzerland site. The new manufacturing complex will occupy an overall footprint of approximately 2,000 m2 with six levels of manufacturing space. The complex will offer several opportunities for future expansions supporting the small molecules technologies offering, which include drug substance, particle engineering technologies such as spray drying dispersion, and drug product.

This construction project is supported by a capital contribution and a tailored long-term collaboration with a major biopharmaceutical partner to ensure continuity of supply and flexibility, supporting future demand for their product. The first buildout represents a dedicated manufacturing line for antibody-drug conjugate payload molecules, which is expected to start its first operations in Q3 2023. Upon completion, the manufacturing complex will employ approximately 200 people.

Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Temperature Instruments Improve Operations
Steel Belt Units for Medical Membranes
Upstream Oil & Gas: Automation intelligence from wellhead to distribution
Video - CoriolisMaster
Video - Do you really need a thermowell?

View More